Apellis Announces Oral Presentation at American Society of Nephrology ( ASN ) Kidney Week on Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN

4 weeks ago

WALTHAM, Mass., Oct. 16, 2024 ( GLOBE NEWSWIRE ) -- Apellis Pharmaceuticals, Inc. ( Nasdaq: APLS ) today announced that the abstract of the Phase 3 VALIANT study of pegcetacoplan in C3 glomerulopathy ( C3G ) and primary immune complex membranoproliferative glomerulonephritis ( IC-MPGN ) was ...

Ticker	Sentiment	Impact
APLS	Neutral	11 %